Microspore and microgametophyte development in relation to biological activity of environmental pollutants.

por Mascarenhas, J P
Publicado 1981

Russell Silver syndrome: a perspective on growth and the influence of growth hormone therapy

por Mascarenhas, J. V., Ayyar, Vageesh S.
Publicado 2012

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

por Mascarenhas, J, Mughal, TI, Verstovsek, S
Publicado 2012

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis

por Verstovsek, S, Atallah, E, Mascarenhas, J, Sun, H, Montgomery, M, Gupta, V, Mesa, R, Gotlib, J
Publicado 2016

P1054: MYLOX-1: AN OPEN-LABEL, PHASE IIA STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR, GB2064, IN MYELOFIBROSIS

por Harrison, C., Mascarenhas, J., Rampal, R., Cilloni, D., Lindmark, B., Singh, B., Jacoby, B., Verstovsek, S.
Publicado 2022

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE...

por Gupta, V., Mascarenhas, J., Kremyanskaya, M., Rampal, R. K., Talpaz, M., Kiladjian, J.-J., Vannucchi, A., Verstovsek, S., Colak, G., Dey, D., Harrison, C.
Publicado 2022

P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE

por Mascarenhas, J., Gerds, A. T., Kish, J. K., Abraham, P., Balanean, A., Nadal, J. A., Liassou, D., Feinberg, B. A., McBride, A., Harrison, C.
Publicado 2022

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE

por Harrison, C., Mascarenhas, J., Abraham, P., Nadal, J. A., Balanean, A., McBride, A., Kish, J. K., Liassou, D., Feinberg, B. A., Gerds, A. T.
Publicado 2022

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA

por Harrison, C., Bose, P., Mesa, R., Gerds, A., Oh, S., Kiladjian, J.-J., García-Gutierrez, V., Vannucchi, A., Scheid, C., Sobas, M., Verstovsek, S., Buckley, S., Roman-Torres, K., Mascarenhas, J.
Publicado 2022

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS

por Kiladjian, J.-J., Tefferi, A., Passamonti, F., Vannucchi, A., Talpaz, M., Cervantes, F., Harrison, C. N., Mesa, R. A., Mascarenhas, J., Schaap, N., Verstovsek, S., Devos, T., Rose, S., Zhang, J., Sy, O., Pardanani, A.
Publicado 2022

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO...

por Mascarenhas, J., Harrison, C. N., Kiladjian, J.-J., Komrokji, R. S., Koschmieder, S., Vannucchi, A. M., Berry, T., Redding, D., Sherman, L., Dougherty, S., Peng, L., Sun, L., Huang, F., Wan, Y., Feller, F. M., Rizo, A., Verstovsek, S.
Publicado 2022

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYEL...

por Harrison, C., Rampal, R. K., Gupta, V., Verstovsek, S., Talpaz, M., Kiladjian, J.-J., Mesa, R., Kuykendall, A., Vannucchi, A., Palandri, F., Grosicki, S., Devos, T., Jourdan, E., Wondergem, M. J., Al-Ali, H. K., Buxhofer-Ausch, V., Alvarez-Larrán, A., Akhani, S., Muñoz-Carerras, R., Sheykin, Y., Colak, G., Harris, M., Mascarenhas, J.
Publicado 2022

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

por Mascarenhas, J, Kosiorek, H, Prchal, J, Yacoub, A, Berenzon, D, Baer, MR, Ritchie, E, Silver, RT, Kessler, C, Winton, E, Finazzi, MC, Rambaldi, A, Vannucchi, AM, Leibowitz, D, Rondelli, D, Arcasoy, MO, Catchatourian, R, Vadakara, J, Rosti, V, Hexner, E, Kremyanskaya, M, Sandy, L, Tripodi, J, Najfeld, V, Farnoud, N, Salama, ME, Weinberg, RS, Rampal, R, Goldberg, JD, Mesa, R, Dueck, AC, Hoffman, R
Publicado 2019